Harmony Biosciences Holdings, Inc.

NasdaqGM HRMY

Harmony Biosciences Holdings, Inc. Dividend Yield on January 14, 2025: 2.66%

Harmony Biosciences Holdings, Inc. Dividend Yield is 2.66% on January 14, 2025, a -11.92% change year over year. Dividend yield measures the dividend per share relative to stock's price value; higher yield suggests higher dividend return.

Harmony Biosciences Holdings, Inc. 52-week high Dividend Yield is 3.37% on June 20, 2024, which is 26.69% above the current Dividend Yield.
Harmony Biosciences Holdings, Inc. 52-week low Dividend Yield is 2.34% on October 29, 2024, which is -12.18% below the current Dividend Yield.
Harmony Biosciences Holdings, Inc. average Dividend Yield for the last 52 weeks is 2.95%.

Key data

Date	Dividend Yield	Free Cash Flow Yield	Earnings Yield	Enterprise Value (EV)

NasdaqGM: HRMY

Harmony Biosciences Holdings, Inc.

CEO	Dr. Jeffrey M. Dayno M.D.
IPO Date	Aug. 19, 2020
Location	United States
Headquarters	630 West Germantown Pike
Employees	246
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Key trends

Past 5 years